Zill-E-Huma Latif

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence

Lars Tanum, Kristin Klemmetsby Solli, Zill-E-Huma Latif et al. · JAMA Psychiatry · 2017 · 253 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone

Zill-E-Huma Latif, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli et al. · JAMA Psychiatry · 2018 · 60 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

No increased pain among opioid‐dependent individuals treated with extended‐release naltrexone or buprenorphine‐naloxone: A 3‐month randomized study and 9‐month open‐treatment follow‐up study

Zill-E-Huma Latif, Kristin Klemmetsby Solli, Arild Opheim et al. · American Journal on Addictions · 2019 · 31 citations

Nursing, Pharmacology, Pharmacotherapy +14

Effectiveness, safety and feasibility of extended‐release naltrexone for opioid dependence: a 9‐month follow‐up to a 3‐month randomized trial

Kristin Klemmetsby Solli, Zill-E-Huma Latif, Arild Opheim et al. · Addiction · 2018 · 28 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)

Nikolaj Kunøe, Arild Opheim, Kristin Klemmetsby Solli et al. · BMC Pharmacology and Toxicology · 2016 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13